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Abstract
Background
As new combinations of interventions aiming at interrupting malaria transmission are under
evaluation, understanding the associated economic costs and benefits is critical for deci-
sion-making. This study assessed the economic cost and cost-effectiveness of the Magude
project, a malaria elimination initiative implemented in a district in southern Mozambique
(i.e. Magude) between August 2015–June 2018. This project piloted a combination of two
mass drug administration (MDA) rounds per year for two consecutive years, annual rounds
of universal indoor residual spraying (IRS) and a strengthened surveillance and response
system on the back of universal long-lasting insecticide treated net (LLIN) coverage and
routine case management implemented by the National Malaria Control Program (NMCP).
Although local transmission was not interrupted, the project achieved large reductions in the
burden of malaria in the target district.
Methods
We collected weekly economic data, estimated costs from the project implementer perspec-
tive and assessed the incremental cost-effectiveness ratio (ICER) associated with the
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Magude project as compared to routine malaria control activities, the counterfactual. We
estimated disability-adjusted life years (DALYs) for malaria cases and deaths and assessed
the variation of the ICER over time to capture the marginal costs and effectiveness associ-
ated with subsequent phases of project implementation. We used deterministic and probabi-
listic sensitivity analyses to account for uncertainty and built an alternative scenario by
assuming the implementation of the interventions from a governmental perspective. Eco-
nomic costs are provided in constant US$2015.
Results
After three years, the Magude project averted a total of 3,171 DALYs at an incremental cost
of $2.89 million and an average yearly cost of $20.7 per targeted person. At an average cost
of $19.4 per person treated per MDA round, the social mobilization and distribution of door-
to-door MDA contributed to 53% of overall resources employed, with personnel and logistics
being the main cost drivers. The ICER improved over time as a result of decreasing costs
and improved effectiveness. The overall ICER was $987 (CI95% 968–1,006) per DALY
averted, which is below the standard cost-effectiveness (CE) threshold of $1,404/DALY
averted, three times the gross domestic product (GDP) per capita of Mozambique, but
above the threshold of interventions considered highly cost-effective (one time the GDP per
capita or $468/DALY averted) and above the recently suggested thresholds based on the
health opportunity cost ($537 purchasing power parity/ DALY averted). A significantly lower
ICER was obtained in the implementation scenario from a governmental perspective ($441/
DALY averted).
Conclusion
Despite the initial high costs and volume of resources associated with its implementation,
MDA in combination with other existing malaria control interventions, can be a cost-effective
strategy to drastically reduce transmission in areas of low to moderate transmission in sub-
Saharan Africa. However, further studies are needed to understand the capacity of the
health system and financial affordability to scale up such strategies at regional or national
level.
Introduction
An infectious disease is considered eliminated in a specific geographical area when its local
transmission is interrupted and maintained at zero [1, 2]. In the long term, the economic ratio-
nale for eliminating infectious diseases is apparent: if elimination is achieved, a high cost-effec-
tiveness and high benefit-cost ratios compared to continued disease control are guaranteed
and constitute the so-called dividend (i.e. the profit of a financial investment) [3]. Long-term
benefits are the result of the improvement of both health and non-health outcomes, such as
management and treatment cost-savings due to reduced cases and deaths, improved produc-
tivity and labour supply, increased educational attainment [4] and literacy rates [5] and higher
lifetime earnings and occupation rates [6], all contributing to economic growth and socioeco-
nomic development.
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While targeting elimination in the long term is desirable—and achievable for several
infectious diseases—, the extremely high costs, combined with the uncertainty and associ-
ated risk of failure, cast doubts on short-term feasibility and efficiency of elimination strate-
gies [7–10]. Equity concerns also factor into decision-making, as during the initial stages
of elimination the less challenging and easy to reach areas and/or groups may be targeted,
often leaving the most vulnerable and poor population aside [11]. Other challenges stem
from the fact that disease elimination is a global public good, characterized by the non-
excludability and non-rivalry attributes in consumption [12]. The ‘global public good’ con-
cept implies that governments need to coordinate financial mechanisms and boost coopera-
tion at the regional level in order to achieve elimination as a common goal. Importantly,
these challenges should not only surface in the last mile preceding the actual achievement of
elimination, but be tackled when decisions on control optimization or pre-elimination ini-
tiatives are being made.
All the issues above need to be addressed in a context of scarce financial resources and
additional pressing public health priorities, where policymakers are faced with key economic
questions such as: (1) are the costs associated with investments towards malaria elimination
affordable and sustainable in a context of competing health challenges?; (2) is the increased
effort associated with implementing interventions towards malaria elimination (with old and/
or new interventions and/or strategies) economically justified in comparison with continuing
with routine control interventions?
By comparing the incremental costs and health effects of elimination initiatives over time
relative to alternative (often business-as-usual) scenarios, cost-effectiveness assessments pro-
vide essential instrumental evidence to answer such questions and inform policy-makers on
how to best prioritize and allocate limited resources in the short term, while monitoring effi-
ciency of activities towards elimination [13].
This debate becomes relevant in the context of malaria, where despite the progress made
in the last decades, the burden of disease remains strikingly high, particularly in sub-Saharan
Africa (SSA). As a result, the World Health Organization (WHO) Global Technical Strategy
for Malaria 2016–2030 (GTS) has urged for the generation of evidence on effective strategies—
using available tools—to accelerate progress towards elimination [14].
The combination of mass drug administration (MDA) for malaria, consisting of door-to-
door administration of antimalarial treatment to every member living in a defined geographi-
cal area on the back of existing prevention and treatment tools, has increasingly received atten-
tion as a promising strategy to rapidly reduce transmission in low to moderate transmission
settings [15]. Although MDA was part of control and elimination strategies during the Global
Malaria Eradication Programme (GMEP) in the 1950s and –60s, evidence on its effectiveness
is limited [16, 17]. Recent studies conducted in Comoros islands, Zambia and South East Asia
[18–20] have reported that MDA using dihydroartemisinin piperaquine (DHAp) is effective in
reducing—although not interrupting—P. falciparum malaria transmission to unprecedented
low levels.
More recently, the Magude project has assessed the feasibility of achieving malaria elimina-
tion in an endemic district in southern Mozambique. Following the GTS recommendations
[14], the project combined an optimized package of existing interventions, including a
strengthened surveillance system, case management, intensified vector control with universal
long-lasting insecticide treated net (LLIN) distribution and universal (i.e. targeted to all house-
holds in the district) indoor residual spraying (IRS), and mass drug administration (MDA)
[21]. The project was based on direct implementation of malaria interventions and was man-
aged on a learning-by-doing basis, with resources for MDA delivery adjusted over time based
on experience accumulation. Effectiveness results of the Magude project align with existing
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evidence [19, 20], indicating that the package of interventions did not interrupt malaria trans-
mission but drastically reduced malaria prevalence and incidence [22].
To date, the debate has largely focused on the impact of MDA on malaria prevalence,
but its cost-effectiveness is poorly understood due to the lack of accurate data on costs and
resources for MDA campaigns. Scarce short and long-term information is available as either
aggregate financial costs from past GMEP elimination experiences, or for very specific settings,
such as islands or emergency scenarios [23], which limits its use in current programme plan-
ning in countries approaching elimination [10].
As a result, knowing the short-term costs and benefits associated with strategies involving
MDA becomes critical to guide policy-makers in prioritizing and sustaining resources while
transitioning from malaria control to malaria elimination. Mozambique is one of the highest
malaria burden and weakest link countries in southern Africa, contributing to cross-border
transmission and impeding the achievement of a malaria-free status in neighbouring countries
[24]. Insights on efficient resource allocation become essential for accelerating progress
towards malaria elimination at the national and regional level.
In this study, the economic resources and cost-effectiveness of the intervention package
implemented in the Magude project are compared with those associated to routine prevention,
diagnosis and treatment interventions under routine malaria control (i.e. annual rounds of
focal IRS, LLIN distribution and standard case management).
Methods
Study site
Magude district is a rural district in Maputo province, southern Mozambique, with 48,448
identified individuals and 10,965 households, according to a baseline census from 2015. The
district has year-round malaria transmission, with seasonal peaks in the rainy season (Novem-
ber–April). Further epidemiological and socio-demographic characteristics of the district have
been described elsewhere [22, 25].
The package of interventions deployed at the district level under the Magude project con-
sisted of: a) a strengthened epidemiological surveillance reporting systems established in the
district since January 2015; b) annual rounds of universal IRS using DDT and/or pirimi-
phos-methyl (Actellic,1) between August–October of 2015, and between September–
November of 2016, 2017 and 2018; c) two yearly rounds of MDA during two consecutive
years, deployed in November 2015 (MDA1), January–February 2016 (MDA2), December
2016 (MDA3) and January–February 2017 (MDA 4) and d) community engagement for
MDA to maximize the acceptance of the intervention followed by e) an active surveillance
system with focal MDA in the index case household, or reactive focal MDA (rfMDA), start-
ing on June 2017 (Fig 1).
The impact of the interventions was estimated by conducting a before-after study and
employing interrupted time series analysis on passively detected weekly malaria cases (by RDT
or microscopy) at the health facilities or by community health workers. MDA coverages varied
between 58–72% across the four rounds, with children under-five years receiving a higher pro-
tection (>70%) in comparison with population older than five (50–70%). Within three years
(August 2015–June 2018), parasite prevalence decreased by 86% and case incidence fell from
195 to 67 cases per 1,000. As a result, an estimated 76.7% of expected cases were averted
(38,369 cases averted of 50,005 expected cases had the intervention not taken place) between
August 2015 and June 2018. Further details on interventions coverages and effectiveness mea-
surement have been reported elsewhere [22].
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Study design
We used an incremental approach from the implementer’s perspective and compared the costs
of the interventions implemented in phase I (between August 2015–2017) and phase II (Sep-
tember 2017–June 2018) of the project (Fig 1) with the costs of routine malaria control (i.e.
counterfactual scenario).
The counterfactual scenario included routine malaria vector control activities implemented
by the government, which include annual rounds of focal IRS (i.e. spraying targeted to high-
burden areas in the district), universal LLIN distributions during national campaigns every
three years, and prompt diagnosis and provision of treatment with efficacious anti-malarial
drugs. According to national guidelines [26], standard case management is delivered at the
health facilities (HF), where malaria testing is performed with rapid diagnostic tests (RDTs)
available at all levels, first-line treatment is artemether-lumefantrine (AL) for uncomplicated
malaria cases and injectable artesunate for all severe cases.
The interventions planned programmatically by the National Malaria Control Programme
(NMCP) that took place in the district simultaneously, including standard case management
as well as a national mass distribution of long-lasting insecticidal treated nets (LLIN), were
also computed as part of the overall package of interventions within the project (Fig 1).
Costs and DALYs
We collected weekly data on the economic resources employed by the project since its incep-
tion in 2015 and developed an ingredient-based costing (micro-costing). Regular meetings
Fig 1. Chronogram of activities and interventions of the Magude project, 2015–2018. Chronogram of the main malaria elimination interventions
implemented in the study district between January 2015 and June 2018, by project year and interventions phase (I and II). MD, mass drug
administration; IRS, indoor residual spraying; rfMDA, reactive focal mass drug administration; LLIN, long-lasting insecticidal nets.
https://doi.org/10.1371/journal.pone.0235631.g001
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were held with each area’s responsible to list the quantity of resources—economic and finan-
cial—utilized in each activity.
Unit costs of purchased resources, disaggregated by commodity and importation price, and
in-country delivery costs, were obtained from the procurement department. For non-financial
items (i.e. resources used by the project in implementing the interventions that did not involve
a financial transaction, such as donated goods or volunteers time), we used data from pub-
lished literature and country evidence (S1 Table). For outsourced activities, such as universal
IRS (implemented by GoodBye Malaria to all households in the district), we revised the exe-
cuted expenditures and organized costing items to fit with our approach.
Costs were depreciated, annualized, inflated, discounted and/or allocated as shared
resources according to methodological guidelines [27–29] and expressed in constant 2015 US$
using average yearly exchange and inflation rates [30, 31] (S1 and S2 Tables). Our analysis did
not consider costs unrelated to the operational aspects of running the project, such as research
costs, and merely approximates the costs incurred by the government if the project was to be
scaled-up to other areas (see S1 Text for details on costing formulas employed).
Cost data associated with routine malaria vector control interventions as part of the coun-
terfactual scenario were gathered from the Global Fund’s Price and Quality Reporting database
(for LLIN,) and the President’s Malaria Initiative country evidence (for IRS) [32]. IRS coverage
rates (52.2%) registered in the Magude demographic census in 2015 were used to estimate the
costs of routine IRS [25].
Standard case management costs associated with the Magude project were calculated
considering the observed malaria cases across time. In addition, case management costs
under the counterfactual scenario were based on the estimated cases had the intervention
not taken place. Treatment unit costs included recurrent costs such as personnel, drugs and
supplies costs incurred in an outpatient visit. For malaria admission, injectable artesunate
treatment and admission costs (assuming an average of 5 days based on expert consultation)
were also considered. Treatment unit costs (for outpatients and inpatients) were gathered
from a previous study carried out in the district and updated from 2007 to 2015 figures
using an inflation rate correction factor [33]. Incremental costs are expressed in net terms,
as they considered cost-savings due to treating fewer malaria cases under the Magude proj-
ect scenario.
We translated the estimated number of malaria cases averted associated with the project
into DALYs averted. Based on evidence from a neighbouring district hospital, we used the
fraction of outpatient visits for malaria that required hospitalization and assumed it to be
equivalent to the percentage of malaria cases that derive into severe malaria (even though not
all inpatients might have been diagnosed with severe malaria). Evidence on inpatient case fatal-
ity rate from the district hospital was used and assumed to reflect the fatality rate of severe
malaria cases (S1 Table).
DALYs averted were estimated by multiplying the number of DALYs lost from malaria
morbidity (severe and non-severe malaria cases) and mortality times the effectiveness of the
project on reducing malaria cases and deaths, respectively [28]. DALYs were discounted and
calculated according to conventional approaches [28] (see S1 Table for key parameters and
sources used in DALYs calculation). Aligned with recent consensus among experts [34],
DALYs have not been aged-weighted in the analysis.
Data analysis
The ICER was calculated by dividing the net incremental costs associated with the Magude
project by the DALYs averted by the project, when compared to routine malaria control
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activities under the counterfactual scenario:
ICER ¼ ½ðCost Magude project þ Cost case management Magude projectÞ   ðCost routine
control þ Cost case management routine controlÞ�=½DALYs associated Magude project 
DALYs associated routine control�
To capture potential economies of scale and scope, we estimated the ICER at three different
timepoints: i) by end year 1, after the deployment of MDA1 and MDA2 (August 2015–Febru-
ary 2016); ii) by end year 2, after the deployment MDA3 and MDA4 (August 2015–February
2017) and iii) by end year 3, one year after the discontinuation of MDA (August 2015–June
2018).
We varied specific parameters to assess their contribution to overall outcomes, understand
key costing drivers and take into consideration univariate uncertainty (S3 Table). We built a
basic alternative scenario in which several parameters were adjusted in order to estimate the
costs of the project if it was implemented by the government. The Magude project imple-
mented from a governmental perspective consisted in adjusting wages and per diems to those
paid by the MoH—according to the corresponding health professional category [35]—and in
considering the use of already existing capital goods within the public health system (i.e. vehi-
cles, warehouses and health structures) and applying the corresponding depreciation rate,
instead of being computed as a purchase or rental. A deterministic threshold sensitivity analy-
sis was performed to estimate the minimum number of cases averted for the Magude project
to be considered cost-effective.
Joint parameter uncertainty was considered by expressing all model inputs as probabilistic
according to appropriate distribution functions [36], with assumed uncertainty range of 20%
applied to each parameter point estimate, except for parameters for which specific evidence
on uncertainty ranges was available (S1 Table), and conducted Monte Carlo simulations
(1,000 iterations).
Probabilistic results were plotted in a cost-effectiveness plane. To define the Magude project
as cost-effective in comparison with routine malaria control (counterfactual scenario), we pri-
marily used standard cost-effectiveness thresholds, based on thresholds of one (highly cost-
effective) to three times (cost-effective) the Mozambican gross domestic product (GDP) per
capita [37], averaged across the period of study. We also graphically represented our results as
acceptability curves, which show the probability of the project of being cost-effective for differ-
ent willingness to pay values, and compared our ICER results with alternative thresholds based
on the health opportunity cost [38].
A long-term scenario was built by extending both the Magude project and counterfactual
scenario costs to 2030. In this modelling exercise, we assumed that the malaria incidence levels
achieved by the project would be maintained with continued vector control and rfMDA as
implemented during the third year. Malaria routine activities and incidence in the counterfac-
tual scenario were assumed to remain stable over time. Malaria incidence figures were adjusted
for population growth rates [39] (see S2 Text for details).
Results
The economic cost of the Magude project over 3 years was $4.33 million, with the four rounds
of MDA being the most resource intense activity, accounting for 53% of overall resources.
With the inclusion of case management costs, at an outpatient and inpatient cost of $1.7 and
$175, respectively, per malaria episode treated, total economic project costs amounted to $4.83
million (Table 1).
PLOS ONE Cost and cost-effectiveness of a malaria elimination campaign in Southern Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0235631 July 6, 2020 7 / 17
Main costing drivers across activities were personnel (39%) and transportation (22%)
resources, followed by malaria drugs and other supplies (19%) (S4 Table). Ten percent of
employed resources included non-financial costs. Non-financial costs were especially present
in activities implemented at the health facilities level, such as those related to strengthening
the surveillance system, given the use of existing resources within the public health system.
Aligned with previous experiences from other door-to-door MDA interventions [23], the
main cost drivers of the community-wide drug administration—with an average cost of
$19.4 per person treated/round—were personnel and transportation. However, MDA costs
decreased by approximately 50% every two rounds, as fewer resources (especially those related
to personal and transportation) were used in a shorter time span, leading to a drop from $26
for rounds 1 and 2 to $13 for rounds 3 and 4 per person treated and per round (S5 Table).
When compared to the counterfactual scenario, the Magude project, at a net incremental
cost of $2.89 million, averted a total 38,369 malaria cases and 3,171 DALYs, leading to a
deterministic ICER of $912 per DALY averted (Table 1). In the base case, the ICER was
lower than the standard cost-effectiveness threshold ($1,404/DALY averted), but higher than
the threshold of interventions considered highly cost-effective ($468/DALY averted) [28].
Results showed that the project would no longer be cost-effective with less than 24,936
malaria cases averted, equivalent to 2,061 DALYs averted. These figures represent a 35%
decrease in effectiveness.
Table 1. Costs of the Magude project vs counterfactual scenario (routine malaria control).
Activity The Magude project Counterfactual
Scenario
Difference Comments
Mean
(US$)
Contr.
(%)
Mean (US$) Mean
(US$)
Epidemiological
surveillance
326,260 8% - 326,260
Mass Drug
Administration
2,297,626 53% - 2,297,626
Community engagement
(for MDA)
224,981 5% - 224,981
Universal IRS 1,243,128 29% - 1,243,128 IRS implemented by the Magude project, targeted to all households in the
district. It achieved operational coverages higher than 90% [23]
Focal IRS - - 473,836 -473,836 IRS implemented by the NMCP, targeted to households in high-burden areas of
the district. It achieved coverage rates of 52.2% [33]. PMI reference unit costs
[32]
rfMDA 186,746 4.31% - 186,746
Universal LLIN
distribution �
54,168 1.25% 54,168 0 Mass LLIN distribution planned programmatically by the NMCP in December
2017
Sub-total 4,332,909 528,005 3,804,904
Case management costs�
Outpatient 35,761 101,444 -65,684 Cost savings due to reduced burden of disease under the Magude Project
Inpatient 462,308 1,311,456 -849,149
Total costs (net) 4,830,977 1,940,905 2,890,072
malaria cases 20,889 59,257 38,369 Averted malaria cases Magude project
DALYs 1,726 4,897 3,171 Averted DALYs Magude project
ICER (deterministic) 912 USD$ / DALY averted
MDA, mass drug administration; IRS, indoor residual spraying; rfMDA, reactive focal mass drug administration; LLIN, long lasting insecticidal nets; NMCP, national
malaria control programme; Contr, contribution; Ref, reference. Costs in constant US$ 2015.
� Interventions planned programmatically by the NMCP
https://doi.org/10.1371/journal.pone.0235631.t001
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The one-way sensitivity analysis reflected that the ICER is extremely sensitive to the malaria
case fatality rate (CFR) (S3 Table; Fig 2a). Changing MDA operational aspects such as field-
workers’ efficiency (in terms of increased number of houses visited per day and per team) and
assuming a constant efficacy rate, also resulted in significantly different MDA cost per capita
and ICER results. On the other hand, results showed little variation to changes in operational
or costing parameters related to IRS implementation (S2 Table; Fig 2b and 2c).
When evaluated over time (by the end of project year 1, year 2 and year 3), the ICER
showed a decreasing trend, reflecting decreased marginal costs but also increased marginal
effectiveness during the project’s implementation timeline (S1 and S2 Figs). Adjusting model
parameters to reflect the Magude project implementation costs from a governmental perspec-
tive (i.e. costs of the same activities when implemented by the NMCP) significantly reduced
the costs (by 32%), leading to an ICER below the highly cost-effectiveness threshold ($441/
DALY averted) (S6 Table and S1 Fig).
Table 2 presents the results from the probabilistic analysis, with an ICER of $987 (CI95%
968–1,006) per DALY averted (incremental cost of $2.89 million [2.86–2.90] and 3,167 incre-
mental DALYs averted [3,111–3,223]), or an equivalent $75 per malaria case averted.
The cost-effectiveness plane plots probabilistic results and suggests that even when account-
ing for parameters’ uncertainty, the project could remain cost-effective by end year 3 (June
2018), with 91% of the simulation points concentrated below the cost-effectiveness threshold
($1,404 per DALY averted) (Fig 3). The acceptability curves complement this information and
show the probability of the project being cost-effective for a range of different willingness to
pay values (to be determined based on governmental preferences, availability of resources,
etc.) per DALY averted (Fig 4) or malaria case averted (S3 Fig).
Finally, basic long-term costing suggests that, under the assumption that the gains achieved
by the Magude project interventions could be sustained through focalized approaches com-
bined with continued vector control and standard case management, as in the third year of the
project [40], the Magude project would potentially become a cost-saving strategy by 2030, with
financial benefits resulting from treating fewer malaria cases exceeding the initial project costs
(S2 Text and S4 Fig).
Discussion
This study shows that the economic cost of the Magude project was substantially higher than
the routine malaria control activities that would have otherwise taken place in the district. In
spite of higher absolute costs, the project was cost-effective by the end of year 3, with an ICER
of $987 (CI95% $968–1,006) per DALY averted, a value below the conventional cost-effective-
ness threshold of three times the GDP per capita (S1 Fig). We estimate that the project would
have still remained cost-effective if achieving at least 65% of the effectiveness (i.e. number of
cases averted) observed. This suggests that the mix of interventions delivered through the
Magude project would potentially remain cost-effective if implemented in less favourable envi-
ronmental and socioeconomic contexts.
The ICER decreased over time, from $7,414 to $987 per DALY averted between the first
and third year of interventions. This contradicts the outcome of previous studies showing an
increasing ratio when optimized malaria control interventions are added [41, 42]. The ICER in
this project decreased as a result of decreasing project costs (at the numerator) and increasing
project effectiveness (at the denominator). Taking into consideration that MDA coverage
remained relatively constant but adherence to the drug regime decreased between rounds (S7
Table), the effectiveness trend may reflect two aspects: (1) the cumulative increasing health
effects of the package of interventions implemented and (2) the high effectiveness of continued
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Fig 2. (a, b, c). Tornado diagram, deterministic sensitivity analysis. The values in the parentheses stand for the lower and higher
range over which the parameter was varied. The vertical line represents the baseline value of the outcome being analysed: ICER in
Fig 2a, MDA cost per person treated/round in Fig 2b and universal IRS cost/person covered in Fig 2c. The blue bars show the
direction and magnitude of change in the outcome of interest, when the input variable is set to its lower range and the red bars show
the direction and magnitude of change when the input variable is set to its higher range. See S1 Table for further details. DALYs,
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intensified vector control and rfMDA in maintaining the gains achieved. The increase in effec-
tiveness could also be driven by environmental factors, given that 2015–16 was an unusual
dry malaria season, whereas 2016–17 was characterized by particularly high rainfall, which
resulted into very low and exceptionally high malaria incidence levels, respectively.
The observed downward cost trend throughout project implementation, on the other hand,
can be explained by a reduction in annualised economic MDA costs from round to round
disability-adjusted life years; MDA, mass drug administration; DHAp, dihydroartemisinin piperaquine; IRS, indoor residual
spraying.
https://doi.org/10.1371/journal.pone.0235631.g002
Table 2. Monte Carlo simulation results of the Magude project.
Differences
Incr Cost (2015 US$) DALYs averted Cases averted ICER (2015 US$)
Range Range Mean Range Mean Median
Magude project end Y1 (1,9181,21–1,933,915) (277–287) 282 3,417 (7,272–7,556) 7,414 6,979
Magude project end Y2 (2,855,967–2,875,219) (1,108–1,148) 1,128 13,668 (2,707–2,811) 2,759 2,590
Magude project end Y3 (2,862,766–2,896,358) (3,111–3,223) 3,167 38,374 (968–1,006) 987 933
https://doi.org/10.1371/journal.pone.0235631.t002
Fig 3. Cost-effectiveness plane. This figure plots the incremental costs (Y axis) and the averted DALYs (X axis) from the Magude project after its first
year (light blue dots), after its second year (orange dots) and after its third year (red dots). The circle represents the 95% ellipse (the 95% credible
interval); the blue dashed line represents the standard high cost-effectiveness threshold equal to one time the gross domestic product per capita ($468
per DALY averted) and the green line represents the standard cost-effectiveness threshold equal to three times the gross domestic product per capita
($1,404 per DALY averted). DALYs, disability-adjusted life years.
https://doi.org/10.1371/journal.pone.0235631.g003
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(from $26 to $13 per person treated) due to the accumulation of know-how (a similar opera-
tional coverage was achieved in rounds 3 and 4, employing nearly half of the workforce from
rounds 1 and 2), the reduced training needs and an improvement in resource planning and
organization [43], together with reduced case management and treatment costs. If a longer
time span is considered, the ICER better reflects the potential cumulative cost-savings that
accrue from reducing the burden of disease (S4 Fig).
Direct comparison of our costs estimates with other door-to-door MDA unit costs would
not be appropriate, given that available evidence refers to very diverse contexts, epidemiologi-
cal settings and MDA specific purposes. However, available estimates—ranging from $1.22 in
Sierra Leone to $14.13 in Comoros Island [23]—also reflect a large share of personnel and
transportation costs used for MDA. In addition, whilst a decreasing marginal unit cost over
time was observed, these estimates reflect the costs associated with the intensification of
malaria control efforts, and not necessarily the costs of reaching the last mile of disease elimi-
nation. Several studies estimating the costs associated with modelled elimination (or even
eradication) found the cost of averting a marginal case to exponentially increase when
approaching the last mile [7, 44]. We can speculate that, should such efforts continue in
Magude, the unit cost would rise until elimination is achieved.
The use of conventional cost-effectiveness thresholds in economic assessments has been
subject to considerable debate. Recent empirical estimates of country-specific opportunity cost
suggest significantly lower thresholds for Mozambique ($ 537 purchasing power parity per
DALY averted or $ 294 unadjusted) [38]. If these estimates were considered in this study, the
project’s cost-effectiveness would be debatable. More importantly, cost-effectiveness thresholds
are only simplified indications on what may constitute a poor, good or very good value for
money, and these should be used alongside other criteria that reflect a country’s affordability
and willingness to pay, as well as other dimensions instrumental in the decision-making pro-
cess (e.g. equity). The acceptability curves provide a broader spectrum for results interpretation
within a context of uncertainty and beyond pre-determined thresholds. If the government
Fig 4. Cost-effectiveness acceptability curve. The acceptability curves show the probability that the Magude project is
cost-effective (compared to continuing with routine malaria control) across time (by end year 1, year 2 and year 3) for
different levels of willingness to pay to avert one DALY (X axis). The vertical lines represent different WTP that can be
applied to Mozambique: US$468 per DALY averted (standard threshold of highly cost-effective intervention; and US
$1,404 per DALY averted (standard threshold of cost-effective intervention). DALYs, disability-adjusted life years.
https://doi.org/10.1371/journal.pone.0235631.g004
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sought a 95% probability of the Magude project being cost-effective, it should be willing to pay
at least $1,500 per DALY averted.
However, one should be careful with the extrapolation of results to other malaria settings.
First, some specific activities that have taken place in the Magude project are not necessarily
an integral part of standard core malaria elimination interventions. Such activities may have
influenced the project’s effectiveness, by steering decisions on key interventions implementa-
tion. For example: a) the demographic census facilitated the identification of households and
residents in the area, enhancing MDA and IRS operational coverage and b) the studies on
insecticide resistance of malaria vectors guided the selection of appropriate insecticides for
effective IRS. The cost imputation of these activities to the project would not only be difficult,
as those refer to research activities implemented for other purposes (i.e. identifying baseline
demographic, epidemiological and entomological indicators from new studies), but also inap-
propriate, given they are not representative of the activities that would be implemented if the
project was replicated at a larger scale. Nonetheless, their inclusion would not have altered our
findings significantly, as the associated costs are relatively small. Second, the project was imple-
mented by external organizations, which means that associated resources and costs do not
reflect those occurring under an implementation in programmatic mode. To illustrate this, by
adjusting salaries to governmental norms and assuming the use of already existing public and
governmental infrastructures, the costs would decrease by 32%. If this program were to be
equally effective, this would translate to an ICER of $441 per DALY averted.
In addition, the presence of potential economies of scope may improve the ICER even fur-
ther. On example are community-based health interventions run by the government as part of
the NMCP or other programmes [45]. MDA programs are operational in Mozambique for the
control and elimination of lymphatic filariasis, schistosomiasis and soil-transmitted helminths
since 2011. As a result, the costs per person treated have diminished by 60% and compliance
rates have improved since initiation of the program [46]. As MDA interventions are scaled-up,
economies of scale can be expected as well [47]. Recent estimates for neglected tropical diseases
point to a cost of less than $0.5 per person when more than 100,000 people are treated [48].
This figure may be achievable for MDA for malaria as well [47].
While other economic questions related to equity, scalability, sustainability and financial
affordability associated with moving from control to pre-elimination remain unanswered,
this study offers solid evidence on the economic rationale for prioritizing resources on innova-
tive strategies that accelerate the progress towards malaria elimination. The micro-costing
approach presented here also provides essential evidence on key inputs for costing extrapola-
tion and scenario development in other settings. Despite the initial high costs and volume of
resources associated with its implementation, MDA in combination with existing malaria con-
trol interventions appears a potentially cost-effective strategy to accelerate towards malaria
elimination in low to moderate transmission settings in SSA.
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22. Galatas B, Saúte F, Martı́-Soler H, Montañà J, Guinovart C, Munguambe H, et al. The Magude project:
a before-after study aiming to eliminate malaria in southern Mozambique. Manuscript under review
(PLos Med). 2020.
23. WHO. Review of delivery cost data on mass adrug administration for malaria. Geneva: 2015.
24. Barrett S. Polio eradication: strengthening the weakest links. Health Aff (Millwood). 2009; 28(4):1079–
90. https://doi.org/10.1377/hlthaff.28.4.1079 PMID: 19597207.
25. Galatas B, Nhacolo A, Marti H, Munguambe H, Jamise E, Guinovart C, et al. Demographic and health
community-based surveys to inform a malaria elimination project in Magude district, southern Mozam-
bique. BMJ Open. 2020; 10(5):e033985. https://doi.org/10.1136/bmjopen-2019-033985 PMID:
32371510
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